These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

584 related items for PubMed ID: 29859099

  • 1. Proteolytic single hinge cleavage of pertuzumab impairs its Fc effector function and antitumor activity in vitro and in vivo.
    Hsiao HC, Fan X, Jordan RE, Zhang N, An Z.
    Breast Cancer Res; 2018 Jun 01; 20(1):43. PubMed ID: 29859099
    [Abstract] [Full Text] [Related]

  • 2. A single proteolytic cleavage within the lower hinge of trastuzumab reduces immune effector function and in vivo efficacy.
    Fan X, Brezski RJ, Fa M, Deng H, Oberholtzer A, Gonzalez A, Dubinsky WP, Strohl WR, Jordan RE, Zhang N, An Z.
    Breast Cancer Res; 2012 Aug 08; 14(4):R116. PubMed ID: 22873525
    [Abstract] [Full Text] [Related]

  • 3. A novel therapeutic strategy to rescue the immune effector function of proteolytically inactivated cancer therapeutic antibodies.
    Fan X, Brezski RJ, Deng H, Dhupkar PM, Shi Y, Gonzalez A, Zhang S, Rycyzyn M, Strohl WR, Jordan RE, Zhang N, An Z.
    Mol Cancer Ther; 2015 Mar 08; 14(3):681-91. PubMed ID: 25552368
    [Abstract] [Full Text] [Related]

  • 4. A monoclonal antibody against hinge-cleaved IgG restores effector function to proteolytically-inactivated IgGs in vitro and in vivo.
    Brezski RJ, Kinder M, Grugan KD, Soring KL, Carton J, Greenplate AR, Petley T, Capaldi D, Brosnan K, Emmell E, Watson S, Jordan RE.
    MAbs; 2014 Mar 08; 6(5):1265-73. PubMed ID: 25517311
    [Abstract] [Full Text] [Related]

  • 5. Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibody.
    Huang S, Li F, Liu H, Ye P, Fan X, Yuan X, Wu Z, Chen J, Jin C, Shen B, Feng J, Zhang B.
    MAbs; 2018 Mar 08; 10(6):864-875. PubMed ID: 30081724
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models.
    Yamashita-Kashima Y, Iijima S, Yorozu K, Furugaki K, Kurasawa M, Ohta M, Fujimoto-Ouchi K.
    Clin Cancer Res; 2011 Aug 01; 17(15):5060-70. PubMed ID: 21700765
    [Abstract] [Full Text] [Related]

  • 8. In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma.
    El-Sahwi K, Bellone S, Cocco E, Cargnelutti M, Casagrande F, Bellone M, Abu-Khalaf M, Buza N, Tavassoli FA, Hui P, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD.
    Br J Cancer; 2010 Jan 05; 102(1):134-43. PubMed ID: 19920829
    [Abstract] [Full Text] [Related]

  • 9. The Proteolytic Cleavage of Therapeutic Monoclonal Antibody Hinge Region: More Than a Matter of Subclass.
    Deveuve Q, Lajoie L, Barrault B, Thibault G.
    Front Immunol; 2020 Jan 05; 11():168. PubMed ID: 32117299
    [Abstract] [Full Text] [Related]

  • 10. The combination of trastuzumab and pertuzumab administered at approved doses may delay development of trastuzumab resistance by additively enhancing antibody-dependent cell-mediated cytotoxicity.
    Tóth G, Szöőr Á, Simon L, Yarden Y, Szöllősi J, Vereb G.
    MAbs; 2016 Oct 05; 8(7):1361-1370. PubMed ID: 27380003
    [Abstract] [Full Text] [Related]

  • 11. A Bispecific Antibody Based on Pertuzumab Fab Has Potent Antitumor Activity.
    Deng W, Liu J, Pan H, Li L, Zhou C, Wang X, Shu R, Dong B, Cao D, Li Q, Wang Z.
    J Immunother; 2018 Jan 05; 41(1):1-8. PubMed ID: 29232309
    [Abstract] [Full Text] [Related]

  • 12. Dysfunctional Antibodies in the Tumor Microenvironment Associate with Impaired Anticancer Immunity.
    Zhang N, Deng H, Fan X, Gonzalez A, Zhang S, Brezski RJ, Choi BK, Rycyzyn M, Strohl W, Jordan R, An Z.
    Clin Cancer Res; 2015 Dec 01; 21(23):5380-90. PubMed ID: 26224871
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Cleavage of IgGs by proteases associated with invasive diseases: an evasion tactic against host immunity?
    Brezski RJ, Jordan RE.
    MAbs; 2010 Dec 01; 2(3):212-20. PubMed ID: 20400859
    [Abstract] [Full Text] [Related]

  • 16. Simultaneous Targeting of FcγRs and FcαRI Enhances Tumor Cell Killing.
    Brandsma AM, Ten Broeke T, Nederend M, Meulenbroek LA, van Tetering G, Meyer S, Jansen JH, Beltrán Buitrago MA, Nagelkerke SQ, Németh I, Ubink R, Rouwendal G, Lohse S, Valerius T, Leusen JH, Boross P.
    Cancer Immunol Res; 2015 Dec 01; 3(12):1316-24. PubMed ID: 26407589
    [Abstract] [Full Text] [Related]

  • 17. Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer.
    Collins DM, Madden SF, Gaynor N, AlSultan D, Le Gal M, Eustace AJ, Gately KA, Hughes C, Davies AM, Mahgoub T, Ballot J, Toomey S, O'Connor DP, Gallagher WM, Holmes FA, Espina V, Liotta L, Hennessy BT, O'Byrne KJ, Hasmann M, Bossenmaier B, O'Donovan N, Crown J.
    Clin Cancer Res; 2021 Feb 01; 27(3):807-818. PubMed ID: 33122343
    [Abstract] [Full Text] [Related]

  • 18. Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy.
    Phillips GD, Fields CT, Li G, Dowbenko D, Schaefer G, Miller K, Andre F, Burris HA, Albain KS, Harbeck N, Dieras V, Crivellari D, Fang L, Guardino E, Olsen SR, Crocker LM, Sliwkowski MX.
    Clin Cancer Res; 2014 Jan 15; 20(2):456-68. PubMed ID: 24097864
    [Abstract] [Full Text] [Related]

  • 19. A new anti-HER2 antibody that enhances the anti-tumor efficacy of trastuzumab and pertuzumab with a distinct mechanism of action.
    Zhang X, Chen J, Weng Z, Li Q, Zhao L, Yu N, Deng L, Xu W, Yang Y, Zhu Z, Huang H.
    Mol Immunol; 2020 Mar 15; 119():48-58. PubMed ID: 31978707
    [Abstract] [Full Text] [Related]

  • 20. Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts.
    McLarty K, Cornelissen B, Cai Z, Scollard DA, Costantini DL, Done SJ, Reilly RM.
    J Nucl Med; 2009 Aug 15; 50(8):1340-8. PubMed ID: 19617342
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.